Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies IA Abela, L Berlinger, M Schanz, L Reynell, HF Günthard, P Rusert, ... PLoS pathogens 8 (4), e1002634, 2012 | 243 | 2012 |
MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1 CR Ruprecht, A Krarup, L Reynell, AM Mann, OF Brandenberg, ... Journal of Experimental Medicine 208 (3), 439-454, 2011 | 129 | 2011 |
Peptic digestion of β-casein: Time course and fate of possible bioactive peptides CEH Schmelzer, R Schöps, L Reynell, R Ulbrich-Hofmann, RHH Neubert, ... Journal of Chromatography A 1166 (1-2), 108-115, 2007 | 94 | 2007 |
HIV vaccines: an attainable goal? L Reynell, A Trkola Swiss medical weekly 142 (0910), w13535-w13535, 2012 | 24 | 2012 |
Therapeutic antibodies in HIV treatment--classical approaches to novel advances. IA Abela, L Reynell, A Trkola Current pharmaceutical design 16 (33), 3754-3766, 2010 | 9 | 2010 |
The HIV genomic incidence assay meets false recency rate and mean duration of recency infection performance standards SY Park, TMT Love, L Reynell, C Yu, TM Kang, K Anastos, J DeHovitz, ... Scientific reports 7 (1), 7480, 2017 | 6 | 2017 |
The HIV genomic incidence assay meets false recency rate and mean duration of recency infection performance standards. PSY Park SungYong, TMT Love, L Reynell, C Yu, ... | | 2017 |